Health Care Related Organization

GSK to Lay Off 150 Employees in Cambridge, Massachusetts Amid Vaccine Manufacturing Shift

1 day ago talkbio0Tagged biotech employment, Cambridge Massachusetts, Drug Industry, layoffs, Marietta Pennsylvania, site transfer, SmithKline Beecham, Vaccines

GSK; layoffs; Cambridge Massachusetts; vaccine manufacturing; site transfer; Marietta Pennsylvania; pharmaceutical industry; biotech employment

AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer

1 day ago talkbio0Tagged AstraZeneca, Benefit, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, life-extension, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Tagrisso

AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit

Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

1 day ago talkbio0Tagged Acquisition, Homo sapiens, Metapneumovirus, Molecular Clamp Technology, non-mRNA vaccine, Respiratory syncytial virus, respiratory vaccines, RSV, sanofi, vaccine pipeline, Vaccines, Combined, Vicebio

Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines

AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia

1 day ago talkbio0Tagged AstraZeneca, Chronic disease, Investments, Manufacturing, R&D, Surgical construction, tariffs, United States, Virginia plant

AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals

FDA Rejects Roche’s Columvi for Earlier-Line Diffuse Large B-Cell Lymphoma

2 days ago talkbio0Tagged Accelerated, Approved, Columvi, Complete, Diffuse Large B-Cell Lymphoma, gemcitabine, genentech, oxaliplatin, Rejection, Response Letter, Roche (company), second, second-line treatment, STARGLO, Third line treatment, United States Food and Drug Administration

FDA rejection; Columvi; Roche; Genentech; diffuse large B-cell lymphoma; DLBCL; STARGLO study; second-line treatment; Complete Response Letter; gemcitabine; oxaliplatin; accelerated approval; third-line therapy

Big Pharma Braces for Potential 200% US Tariffs Amid Uncertainty

5 days ago talkbio0Tagged Donald Trump, Drug Industry, drug price, Health Care Systems, Manufacturing, onshoring, supply chains, tariffs

pharmaceutical industry; tariffs; Donald Trump; supply chains; onshoring; drug prices; manufacturing; healthcare system

Bristol Myers Squibb and Pfizer Launch Direct-to-Consumer Discount Program for Eliquis

6 days ago talkbio0Tagged Anticoagulants, blood thinner, Direct-to-Consumer, Eliquis, Myers, online program, Pfizer, squibb

Bristol Myers Squibb; Pfizer; Eliquis; direct-to-consumer; discount; online program; Eliquis 360 Support; anticoagulant; blood thinner; patient access

Pfizer Warns of ‘Near-Term Stock Out’ of Penicillin Used for Treating Syphilis in Pregnant Women After Recall

6 days ago talkbio0Tagged Bicillin L-A, Drug Shortage, Extencilline, penicillin recall, Pfizer, Pregnant Women, public health medicine (field), syphilis treatment, Syphilis, Congenital, United States Food and Drug Administration

Pfizer; penicillin recall; Bicillin L-A; syphilis treatment; pregnant women; drug shortage; congenital syphilis; FDA; Extencilline; public health

Thermo Fisher to Acquire Sanofi Factory; Amphastar Plans Major HQ Expansion

6 days ago talkbio0Tagged Acquisition, Amphastar, California, capacity quadruple, expansion, fill-finish, headquarters, pharmaceutical manufacturing, Ridgefield New Jersey, sanofi, sterile manufacturing, Thermo Fisher

Thermo Fisher; Sanofi; acquisition; sterile manufacturing; Ridgefield New Jersey; fill-finish; pharmaceutical manufacturing; Amphastar; headquarters expansion; capacity quadruple; California

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

1 week ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development